Onxeo to acquire DNA Therapeutics

1 March 2016

French orphan oncology Onxeo (Euronext Paris: ONXEO) has reached an agreement to acquire DNA Therapeutics, a privately-held, clinical-stage French biopharmaceutical company, for its signal-interfering DNA (siDNA) repair technology, which is directed at overcoming cancer resistance mechanisms, and includes lead product candidate DT01.

The acquisition, which is subject to customary closing conditions, is expected to complete by the end of March 2016. Shares of Onxeo, itself created in 2014 by a merger between French company BioAlliance Pharma, and Danish biopharmaceutical company Topotarget, were up 3.8% at 3.00 euros in mid-morning trading.

The acquisition of DNA Therapeutics continues to demonstrate Onxeo's commitment to developing novel orphan oncology drugs that position the company at the forefront of scientific research for rare cancers with high, unmet medical needs, and have the potential to generate significant value for the Company and its stakeholders by opening other indications and markets, the French firm said.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK